Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 versus placebo for TSC-associated SEGA
NL-OMON37063Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subependymal giant cell astrocytoma (SEGA) and tuberous sclerosis complex (TSC) comparing Everolimus with Placebo (2 arms). Primary endpoint: SEGA response rate. Started Aug 2010; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
subependymal giant cell astrocytoma (SEGA)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NL-OMON37063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37063.